Deep vein thrombosis & Pulmonary Embolism: Unstable angina, acute peripheral arterial occlusion, prophylaxis in orthopaedic surgery:
Deep vein thrombosis & Pulmonary Embolism: I.V loading dose: 5000 - 10,000 units depending on severity of the condition. This is followed by 1000-2000 units/hour by continuous infusion or 15,000 units after every 12hours SC. Children or young adults: Reduce loading dose then 15-25/kg/hour by I.V infusion or 250 units/kg SC. every 12hours. Unstable angina, acute peripheral arterial occlusion, prophylaxis in orthopaedic surgery [See above dosages]. Prophylaxis in general surgery: SC. 5000 units 2 hours before surgery then TID to QID for 7 days or until the patient is ambulant. During pregnan- cy; 5000-10,000 units BD. [Laboratory monitor- ing essential].
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Heparin interacts with anti- thrombin III heparin cofactor to produce a sub- stance that immediately neutralizes thrombin by forming a complex with it at its active serine center. It also inhibits platelet function, increases the permeability of vessel walls, inhibits the proliferation of vascular smooth muscle cells, inhibits delayed hypersensitivity reactions, and is involved in the regulation of angiogenesis.
To screen all patients before initia- tion of heparin therapy to rule out bleeding disorders; to discontinue immediately in case of the bleeding; monitoring of platelet counts before and during heparin therapy.
Patients with severe thrombo- cytopenia; patients with excessive bleeding disorder[s]; patients who are hypersensitive to the drug.
Haemorrhage as the extension of its action; thrombocytopenia caused by a direct non- immunologic effect on circulating platelets; thrombocytopenia caused by the heparin- dependent IgG platelet-aggregating antibody; localized or disseminated thromboses [rare]; hypersensitivity [rare]; deep subcutaneous injec- tion of heparin may cause local irritation [rare], erythema, mild pain, hematoma, ulceration, or cutaneous and subcutaneous necrosis.
is a heterogeneous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans, having anticoagulant properties. It isstrongly acidic because of its content of covalently linked sulphate and carbox- ylic acid groups. It is derived from bovine lung tissue or porcine intestinal mucosa. It is a paren- teral anti-coagulant with both short onset and short duration of action.